NCT05558410

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,118 (actual)
• Sponsor: Vertex Pharmaceuticals Incorporated · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.

Conditions

• Acute Pain

Interventions

Type	Name	Description
DRUG	Suzetrigine (SUZ)	Tablets for oral administration.
DRUG	HB/APAP	Capsules for oral administration.
DRUG	Placebo (matched to SUZ)	Placebo matched to SUZ for oral administration.
DRUG	Placebo (matched to HB/APAP)	Placebo matched to HB/APAP for oral administration.

Timeline

• Start date: 2022-10-10
• Primary completion: 2023-08-25
• Completion: 2023-09-11
• First posted: 2022-09-28
• Last updated: 2025-07-01
• Results posted: 2025-07-01

Locations

12 sites across 1 country: United States

Regulatory

• FDA-regulated drug study